Stoke Therapeutics, Inc. STOK Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s stock issuance proceeds?
- Stoke Therapeutics, Inc. (STOK) reported stock issuance proceeds of $3.21M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Stoke Therapeutics, Inc.'s stock issuance proceeds increased by 219.2% year-over-year, from $1M to $3.21M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s stock issuance proceeds?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s stock issuance proceeds has grown at a 82.4% compound annual growth rate (CAGR), from $777K to $8.6M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.